wire - news in brief

« BACK

Medicine/Pharmacology



Results 1 - 50 of 1156.
1 2 3 4 5 ... 24 Next »

Medicine/Pharmacology - Life Sciences
27.06.2017
Sandoz receives approval in Europe for Erelzi (biosimilar etanercept) to treat multiple inflammatory diseases
European Commission approves Sandoz Erelzi to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis Approval of Erelzi provides more treatment options for heal
Medicine/Pharmacology - Administration/Government
27.06.2017
Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)
Fewer pills, more flexibility in dosing: Roche's new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of
Medicine/Pharmacology - Life Sciences
26.06.2017
Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors
Roche's emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting Roche today announced positive data from the p
Medicine/Pharmacology - Life Sciences
23.06.2017
NEJM publishes full analysis of Rydapt (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved eve
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor CHMP opinio
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data † Data evaluating 63 patients demonstrate relapse-free survival and probability of survival in a majority of patients at six months † Advances in CTL019 and ELIANA result from global CAR-T cell therapy collaboration with the University of Pennsylvania † CTL019 is manufactured us
Medicine/Pharmacology - Chemistry
23.06.2017
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna
New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP patients in ENESTfreedom and ENESTop who stopped Tasigna and were in TFR at 48 weeks remained in TFR at 96 weeks [1,2] 48-week data from same trials recently added to Tasigna SmPC following EC approval; discussions with other regulatory authorities are underway worldwide - Novartis toda
Medicine/Pharmacology - Life Sciences
23.06.2017
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers First in class BCL2-specific oral inhibitor represents a potential new way of treating different blood cancers Efficacy and tolerability confirmed in high-risk patients with relapsed or refractory chronic lymphocytic leukaemia, including those with 17p chromosomal de
Medicine/Pharmacology - Physics/Materials Science
23.06.2017
Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma
Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Longer follow-up showed sustained benefit in progression-free survival of Gazyva/Gazyvaro-based treatment over MabThera/Rituxan-based treatment regardless of chemotherapy regimens People with follicular lymphoma who received Gazyva/Gazyvaro-based treatment reported improvement in health-related qualit
Medicine/Pharmacology - Life Sciences
23.06.2017
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes, compared to 1.5 hour
Medicine/Pharmacology - Life Sciences
23.06.2017
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC) Approval provides first targeted treatment in the U
Medicine/Pharmacology
22.06.2017
ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis † Despite current treatments about 40% of heart attack survivors remain at increased risk of† recurrent heart attack, stroke or cardiovascular death because of hi
Medicine/Pharmacology - Life Sciences
21.06.2017
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance † Filing is supported by a comprehensive clinical program o
Medicine/Pharmacology
20.06.2017
Almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by study of over 3,700 patients , 42% of CU patients studied are not receiving any treatment for their debilitatin
Medicine/Pharmacology
20.06.2017
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48 , in two head-to-head pivotal Phase III†studies , † 57% and 52% of patients receiving RTH258 6 mg in the respective trials were maintained exclusively on a q12w interval immediately following the loading phase and continuing through week 48 , † In both studies overall ocular and non-ocular adverse event rates for RTH258
Medicine/Pharmacology - Life Sciences
19.06.2017
Sandoz receives approval in Europe for Rixathon‚? (biosimilar rituximab) to treat blood cancers and immunological diseases
European Commission approves Sandoz Rixathon ‚? to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.
Medicine/Pharmacology
17.06.2017
Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
Large-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease ‚? These new data underscore the disconnect between self-perceived control and clinical reality; a potentially limiting factor in patients seeking support to better control their condition ‚? Helping patients recognize the possibilities of living a life with properly controlled asthma is central to a major new global p
Medicine/Pharmacology - Life Sciences
16.06.2017
Bacteria Free Themselves with Molecular ‘Speargun'
Bacteria Free Themselves with Molecular ‘Speargun’
Many bacteria are armed with nano-spearguns, which they use to combat unwelcome competitors or knockout host cells.
Medicine/Pharmacology
15.06.2017
Novartis’ Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
Cosentyx ‚? is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) , ‚? Additional data show rapid and sustained pain relief with Cosentyx as early as Week 3 which is sustained out to 2 years in PsA patients ‚? Patient recruitment underway for the new EXCEED head-to-head clinical trial to show superiority of Cosentyx versus Humira ‚? * in PsA The di
Life Sciences - Medicine/Pharmacology
15.06.2017
Gene Transfer Keeps Bacteria Fit
Gene Transfer Keeps Bacteria Fit
Researchers at the University of Basel‚?‘s Biozentrum have discovered that Bartonella bacteria exchange genes efficiently using a domesticated virus encoded in their genome.
Medicine/Pharmacology
15.06.2017
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus‚?
FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus ‚? Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicin
Medicine/Pharmacology - Life Sciences
13.06.2017
Boost for Zurich biomedicine
Boost for Zurich biomedicine
The Helmut Horten Foundation has supported Zurich's medical hub for many years. Now, a new donation to ETH will enable the strengthening of the Zurich-Ticino ‘health axis'.
Medicine/Pharmacology - Physics/Materials Science
13.06.2017
New "WHO Collaborating Centre for Physical Activity and Health"
A lack of physical activity increases the risk for cardiovascular and respiratory diseases as well as diabetes and cancer.
Life Sciences - Medicine/Pharmacology
12.06.2017
Fighting fire blight and detecting Salmonella
Fighting fire blight and detecting Salmonella
ETH researchers have created an effective weapon against the plant disease fire blight and a new method for detection of Salmonella. Both are based on particular viruses that attack only one species of bacteria. The plant disease fire blight, caused by the bacterium Erwinia amylovora , is dreaded by fruit growers.
Life Sciences - Medicine/Pharmacology
12.06.2017
Uncovering the biology of a painful and disfiguring pediatric disease
Uncovering the biology of a painful and disfiguring pediatric disease
EPFL scientists have identified the biological mechanism behind the painful, potentially lethal, disfiguring Hyaline Fibromatosis Syndrome.‚? Image caption:‚?Loss of ANTXR2 leads to the accumulation of extracellular material in mice uterus and sterility (Left). Collagen 6 removal in mice without ANTXR2 restore uterine structure and function (Right).
Medicine/Pharmacology - Business/Economics
09.06.2017
Hybrid membrane creates a stir on the global market
Hybrid membrane creates a stir on the global market
ETH Professor Raffaele Mezzenga and his senior researcher Sreenath Bolisetty have developed a filter membrane that efficiently removes heavy metals and other toxic substances from water. Strong demand for the new technology has encouraged them to set up a new ETH spin-off, BluAct Technologies. The news story made a big splash: in January 2016 ETH researchers Professor Raffaele Mezzenga and his senior researcher Sreenath Bolisetty published a study about an innovative type of membrane developed in their laboratory.
Medicine/Pharmacology - Life Sciences
08.06.2017
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month ‚?
Medicine/Pharmacology - Life Sciences
07.06.2017
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43% achi
Mathematics - Medicine/Pharmacology
07.06.2017
Your own virtual heart for non-invasive heart diagnostics
EPFL mathematician Alfio Quarteroni and his team are building a virtual heart model based on personalized medical images that may one day help cardiologists and cardiac surgeons non-invasively diagnose pathological heart conditions.
Medicine/Pharmacology - Chemistry
06.06.2017
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials evaluating TFR with Tasigna in Ph+ CML-CP patients in both the first-line setting and after switching from Glivec ‚?
Medicine/Pharmacology - Life Sciences
05.06.2017
Phase III study showed Roche‚? s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
Phase III study showed Roche‚??s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system Data will be simultaneously pub
Medicine/Pharmacology - Computer Science/Telecom
05.06.2017
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
Collaboration will use real-world patient data and cognitive computing with aim of improving outcomes in advanced breast cancer Brings Novartis innovation and breast cancer expertise together with IBM Watson Health proficiency in data analytics and machine learning Collaboration initiating in breast cancer given Novartis heritage and expertise; opportunity to expand to enhance outcomes for patients with other cancers ‚‘‚'‚‘‚'‚‘‚'‚‘‚'‚‘‚'‚‘‚' ‚?
Medicine/Pharmacology - Administration/Government
05.06.2017
Roche‚? s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
APHINITY study shows Roche‚??s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Phase III study confirms
Medicine/Pharmacology
05.06.2017
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
Phase I/II study to evaluate Mekinist ‚? (trametinib) in combination with Opdivo ‚? (nivolumab) and Opdivo + Yervoy ‚? (ipilimumab) ‚? Collaboration expands upon existing clinical investigation of Op
Medicine/Pharmacology - Life Sciences
04.06.2017
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
Novartis landmark study of Tafinlar‚? + Mekinist‚? demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma Study is longest follow-up to date o
Medicine/Pharmacology - Life Sciences
03.06.2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017
Roche presents new data for TECENTRIQ‚? (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 Data evaluated TECENTRIQ in novel combinations across a broad range of tumours including lung, kidney and melanoma Promising Phase II combination data with TECENTRIQ plus Avastin (bevacizumab) in advanced kidney cancer First treatment-beyond-progression data from a Phase III study of cancer immunotherapy in a
Medicine/Pharmacology - Life Sciences
02.06.2017
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
Novartis presents updated data that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer At a subsequent
Medicine/Pharmacology - Life Sciences
02.06.2017
A new approach to combatting anxiety states, pain and inflammation
A new approach to combatting anxiety states, pain and inflammation
Media releases, information for representatives of the media Media Relations (E) Endogenous cannabinoids (endocannabinoids) play an important role in the brain and immune system. Bern researchers from the National Centre of Competence in Research (NCCR) "TransCure" have now found a new way to influence the endocannabinoid system.
Medicine/Pharmacology
31.05.2017
Progress reported in global fight against diarrheal disease cryptosporidiosis
Novartis, the University of Georgia, Washington State University and collaborators advance therapeutic research for cryptosporidiosis Research collaboration with novel drug discovery process counters slow progress in developing new cryptosporidiosis treatments Scientists report discovery of Cryptosporidium PI(4)K inhibitor candidate KDU731 in new issue of Nature - Infectious disease scientists from Novartis, the University of Georgia and Washing
Medicine/Pharmacology - Business/Economics
31.05.2017
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018 Building depth across key therapeutic areas wi
Medicine/Pharmacology - Life Sciences
31.05.2017
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira * and Remicade ** Comprehensive data pac
Medicine/Pharmacology - Life Sciences
31.05.2017
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months. CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the University of Pennsylvania Novartis is committed to advancing a portfolio of next-generation CAR-T cell therapies - Novartis announced findings from a pilot study (NCT02640209) of CTL119 in combination with ibrutinib* in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who had been taking ibrutinib for at least six months and who were not in complete remission.
Medicine/Pharmacology - Life Sciences
30.05.2017
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Resistant Cancer Cells: 3D Structure of a Drug Transporter Decoded
Drug resistance is not only a major problem in fighting infectious diseases. Also in the treatment of cancer it can jeopardize the success of chemotherapy.
Medicine/Pharmacology - Life Sciences
26.05.2017
Designer Viruses Stimulate the Immune System to Fight Cancer
Swiss scientists have created artificial viruses that can be used to target cancer. These designer viruses alert the immune system and cause it to send killer cells to help fight the tumor. The results, published Communications, provide a basis for innovative cancer treatments. Most cancer cells only provoke a limited reaction from the immune system – the body's defense mechanism – and can thus grow without appreciable resistance.
Medicine/Pharmacology - Life Sciences
26.05.2017
Novartis receives FDA approval for expanded use of Zykadia in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival (PFS) was 16.6 months, compared to 8.1 months with chemotherapy † The overall intracranial response r
Medicine/Pharmacology - Administration/Government
24.05.2017
New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)
New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) In new post hoc analyses of phase III data, Esbriet reduced the risk of death in p
Life Sciences - Medicine/Pharmacology
23.05.2017
Revealing how neurons communicate
Revealing how neurons communicate
The ETH spinoff MaxWell Biosystems AG develops microelectrode platforms for electrophysiological tests on nerve cells, opening up new possibilities for pharmaceutical research. Now, the company received CHF 130,000 in starting capital from the Venture Kick initiative MaxWell Biosystems AG's head office is hidden away in a Basel laboratory building previously used by Syngenta, just a stone's throw from ETH Zurich's Department of Biosystems Science and Engineering (D-BSSE).
Medicine/Pharmacology - History/Archeology
23.05.2017
Novartis’ new analyses reinforce the potential of Ultibro Breezhaler for COPD patients historically treated with steroids
New analyses from the FLAME study suggest dual bronchodilator Ultibro Breezhaler provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil (a type of white blood cell)† counts † Data was published in the centenary issue of the American Thoracic Society's 'American Journal of Respiratory and Critical Care Medicine' † Together with the International Primary Care Respiratory Group, Novartis is launching
Medicine/Pharmacology - Life Sciences
23.05.2017
Discovery of a Key Regulatory Gene in Cardiac Valve Formation
Researchers from the University of Basel in Switzerland have identified a key regulator gene for the formation of cardiac valves - a process crucial to normal embryonic heart development. These results are published in the journal Cell Reports today. The heart is the first functional organ that develops in vertebrate embryos.
Medicine/Pharmacology - Life Sciences
23.05.2017
FDA approves Roche’s Actemra/RoActemra (tocilizumab) for giant cell arteritis
FDA approves Roche's Actemra/RoActemra (tocilizumab) for giant cell arteritis Actemra/RoActemra is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA Sixth FDA approval for Actemra/RoActemra since its US launch in 2010 Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra /RoActemra (tocilizumab) ) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition.
1 2 3 4 5 ... 24 Next »